Since announcing their partnership in April 2025, AstraZeneca and Revna Biosciences have made significant strides in improving lung cancer care across Ghana, from early diagnosis to access to advanced targeted treatments. A major milestone was reached with the launch of AstraZeneca’s targeted therapy for patients with EGFR-mutated lung cancer, marking a critical step in bringing cutting-edge treatments to sub-Saharan Africa.
Dr. Derrick Edem Akpalu, Co-Founder and CEO of Revna Biosciences, emphasized how the collaboration leverages a biomedical ecosystem to overcome long-standing barriers in access to molecular diagnostics and targeted therapies. “By integrating advanced diagnostics, data, and treatment pathways, we are enabling a new standard of care for patients who have historically been underserved,” he said.
The partnership’s achievements include building oncology treatment capacity through strategic workshops and symposia, operationalizing EGFR biomarker testing at leading cancer centers, and establishing a scalable infrastructure that connects diagnostics to personalized treatment pathways, reducing the time to therapy.
AstraZeneca’s Medical Director for the African Cluster, Dr. Khomotso Mashilane, highlighted the impact of the collaboration: “By combining advanced diagnostics with access to targeted anti-cancer therapies, we are helping to ensure that patients receive the right treatment at the right time. This is a testament to the power of science and collaboration in transforming cancer care.”
Together, AstraZeneca and Revna Biosciences are laying a future-ready foundation with real-time data integration to support clinical decision-making and regional research on molecular profiling and treatment response, driving lasting improvements in lung cancer outcomes in Ghana and beyond.